Regencell Bioscience (NASDAQ:RGC) Stock Price Down 4.4% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price dropped 4.4% during trading on Thursday . The company traded as low as $19.75 and last traded at $19.5450. Approximately 11,985 shares traded hands during mid-day trading, a decline of 96% from the average daily volume of 282,055 shares. The stock had previously closed at $20.45.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Regencell Bioscience Stock Performance

The firm’s 50 day simple moving average is $27.18 and its 200 day simple moving average is $25.61.

Regencell Bioscience (NASDAQ:RGC) last announced its earnings results on Friday, May 8th. The company reported $0.00 earnings per share for the quarter.

Institutional Trading of Regencell Bioscience

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RGC. Squarepoint Ops LLC purchased a new stake in Regencell Bioscience in the 2nd quarter worth about $1,701,000. BNP Paribas Financial Markets purchased a new stake in Regencell Bioscience in the 2nd quarter worth about $768,000. XTX Topco Ltd purchased a new stake in Regencell Bioscience in the 3rd quarter worth about $598,000. Hudson Bay Capital Management LP purchased a new stake in Regencell Bioscience in the 4th quarter worth about $275,000. Finally, Vident Advisory LLC raised its position in Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after purchasing an additional 11,866 shares during the period. 0.13% of the stock is owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.